Rating upgraded from 79 to 82 Wednesday.Please watch the video at Investors.com - How To Scale Out Of Losing Stocks Using These Three SignalsRisk Management In The Stock Market: How Much Money To ...

The necessity of ensuring the U.S. has a domestic supply of rare-earth minerals and magnets is behind this stock's astonishing rise in 2025.

Net cash provided by operating activities reached $10.1 million, with an average DSO of 55.9 days in Q3 2025. The company ...

Kymera Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 84.